Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the target of unusually large options trading activity on Wednesday. Traders purchased 4,572 call options on the stock. This is an increase of 725% compared to the typical daily volume of 554 call options.

Ventyx Biosciences Stock Down 7.9%

VTYX stock opened at $2.44 on Thursday. The company’s 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.75. Ventyx Biosciences has a 52-week low of $0.78 and a 52-week high of $3.40. The firm has a market cap of $173.63 million, a P/E ratio of -1.03 and a beta of 0.85.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. On average, analysts anticipate that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VTYX. Rhumbline Advisers raised its position in shares of Ventyx Biosciences by 44.4% during the 4th quarter. Rhumbline Advisers now owns 132,825 shares of the company’s stock worth $291,000 after purchasing an additional 40,813 shares during the last quarter. Palumbo Wealth Management LLC raised its position in shares of Ventyx Biosciences by 97.1% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock worth $52,000 after purchasing an additional 11,792 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Ventyx Biosciences by 88.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company’s stock worth $1,909,000 after purchasing an additional 409,357 shares during the last quarter. Monaco Asset Management SAM acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $526,000. Finally, Virtu Financial LLC acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $189,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.